Literature DB >> 18631968

Preference-based quality of life in patients with Alzheimer's disease.

Jason H Karlawish1, Art Zbrozek, Bruce Kinosian, Annemarie Gregory, Allison Ferguson, Henry A Glick.   

Abstract

BACKGROUND: This study was developed to evaluate the feasibility, reliability, and validity of use of patients' ratings of health preference measures as outcomes for cost-effectiveness analyses in persons with very mild to moderate Alzheimer's disease (AD).
METHODS: Patients and caregivers completed ratings of the EuroQol-5D system (EQ-5D) and the Health Utilities Index Mark 2 (HUI2) and instruments that assess cognition, mood, insight, AD-specific and generic health-related quality of life (QOL) and activities of daily living.
RESULTS: Patients' HUI2 scores were reliable. EQ-5D scores were somewhat less so. Patients rated their utility high, with overall EQ-5D and HUI2 scores greater than 0.8. Neither the EQ-5D nor the HUI2 scores had a relationship with severity of cognitive impairment. Both the EQ-5D and the HUI2 had expected relationships with patient-rated measures of QOL, function, mood, and specific subscales we hypothesized should be associated with patient preferences. Patient insight into functional and cognitive impairments had little association with their health preference scores.
CONCLUSIONS: AD patients' scores on the EQ-5D and the HUI2 have many of the characteristics of valid preference measures. However, the proportions of persons who do not perceive any disability, the lack of association with the caregivers' ratings of activities of daily living, limited associations with insight, and no association with their Mini-Mental State Exam scores suggest that patients' reports of disability might reflect legitimate self-perceptions of mood and function that are associated with comorbidities rather than with AD.

Entities:  

Mesh:

Year:  2008        PMID: 18631968     DOI: 10.1016/j.jalz.2007.11.019

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  14 in total

1.  Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.

Authors:  Gary Naglie; David B Hogan; Murray Krahn; B Lynn Beattie; Sandra E Black; Chris Macknight; Morris Freedman; Christopher Patterson; Michael Borrie; Howard Bergman; Anna Byszewski; David Streiner; Jane Irvine; Paul Ritvo; Janna Comrie; Matthew Kowgier; George Tomlinson
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

2.  Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.

Authors:  Gary Naglie; David B Hogan; Murray Krahn; Sandra E Black; B Lynn Beattie; Christopher Patterson; Chris Macknight; Morris Freedman; Michael Borrie; Anna Byszewski; Howard Bergman; David Streiner; Jane Irvine; Paul Ritvo; Janna Comrie; Matthew Kowgier; George Tomlinson
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

3.  Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.

Authors:  Keyvan Mirsaeedi-Farahani; C H Halpern; G H Baltuch; D A Wolk; S C Stein
Journal:  J Neurol       Date:  2015-03-06       Impact factor: 4.849

4.  Measuring health-related quality-of-life for Alzheimer's disease using the general public.

Authors:  Feng Xie; Mark Oremus; Kathryn Gaebel
Journal:  Qual Life Res       Date:  2011-07-09       Impact factor: 4.147

5.  Mapping the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III.

Authors:  Yin Bun Cheung; Hui Xing Tan; Vivian Wei Wang; Nagaendran Kandiah; Nan Luo; Gerald C H Koh; Hwee Lin Wee
Journal:  Qual Life Res       Date:  2018-09-01       Impact factor: 4.147

6.  Quality of life in nursing home residents with advanced dementia.

Authors:  Zachary Cordner; David M Blass; Peter V Rabins; Betty S Black
Journal:  J Am Geriatr Soc       Date:  2010-11-04       Impact factor: 5.562

7.  Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.

Authors:  Tzeyu L Michaud; Robin High; Mary E Charlton; Daniel L Murman
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jul-Sep       Impact factor: 2.703

Review 8.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

9.  An intervention to promote self-management, independence and self-efficacy in people with early-stage dementia: the Journeying through Dementia RCT.

Authors:  Gail Mountain; Jessica Wright; Cindy L Cooper; Ellen Lee; Kirsty Sprange; Jules Beresford-Dent; Tracey Young; Stephen Walters; Katherine Berry; Tom Dening; Amanda Loban; Emily Turton; Benjamin D Thomas; Emma L Young; Benjamin J Thompson; Bethany Crawford; Claire Craig; Peter Bowie; Esme Moniz-Cook; Alexis Foster
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

10.  How does the canadian general public rate moderate Alzheimer's disease?

Authors:  Jean-Eric Tarride; Mark Oremus; Eleanor Pullenayegum; Natasha Clayton; Parminder Raina
Journal:  J Aging Res       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.